

# TABLE OF CONTENTS

<b>0. Executive Summary .....</b>	<b>19</b>
<b>1. Introduction .....</b>	<b>23</b>
<b>Definitions .....</b>	<b>23</b>
<b>Historical development of neuroprotection .....</b>	<b>23</b>
<b>Intrinsic neuroprotective factors .....</b>	<b>24</b>
Neuroprotective gene expression .....	25
Neurotrophic factors.....	25
Intrinsic non-enzymatic antioxidants .....	26
Intrinsic neuroprotective proteins.....	26
<i>Excitatory amino acid transporters (EAATs)</i> .....	26
<i>Extracellular serine protease thrombin</i> .....	26
<i>Neuroglobin</i> .....	27
<i>Galanin</i> .....	27
<i>Prion protein</i> .....	28
<i>Rai (Shc C) adaptor protein</i> .....	28
Stem cell factor .....	28
Role of the immune system in neuroprotection .....	28
Induction of DNA repair enzymes for neuroprotection .....	29
<b>Pathomechanisms of CNS injury as basis for neuroprotection .....</b>	<b>29</b>
<b>Biomarkers of neurological disorders and neuroprotection.....</b>	<b>30</b>
CNS biomarker identification using proteomics .....	30
Brain imaging for detection of biomarkers .....	31
<b>Role of neuroprotection in various neurological disorders .....</b>	<b>31</b>
<b>Neuroprotection and neuroregeneration.....</b>	<b>32</b>
<b>Acute versus chronic neuroprotection .....</b>	<b>32</b>
<b>Discovery and evaluation of neuroprotective agents .....</b>	<b>33</b>
Neuroprotective drug discovery .....	33
Discovery of CNS drugs that penetrate the blood-brain barrier .....	33
In vitro assays for the evaluation of neuroprotective agents .....	34
Oxidative injury model to test neuroprotective drugs.....	34
Apoptosis model for designing neuroprotective drugs .....	34
Transgenic mouse models of neurological disorders.....	35
Brain-on-a-Chip™ technology .....	35
Evaluating effects of neuroprotective drugs on living brain slices.....	35
Role of brain imaging in neuroprotective drug discovery and development .....	36
<i>Positron emission tomography</i> .....	36
<i>Role of single photon emission computed tomography</i> .....	37
<i>Functional CT scanning to evaluate cerebrovascular protection</i> .....	37
<i>Magnetic resonance imaging for the evaluation of neuroprotectives</i> .....	37
Application of nanotechnology to neuroprotection .....	38
Evaluation criteria for potential neuroprotective agents.....	38
Evaluation of neuroprotective effect of drugs approved for other indications.....	38
<b>2. Neuroprotective Agents .....</b>	<b>39</b>
<b>Classification of neuroprotective agents .....</b>	<b>39</b>
<b>Activated protein C .....</b>	<b>43</b>
<b>Activity-dependent neuroprotective protein .....</b>	<b>44</b>
<b>Adenosine analogs.....</b>	<b>44</b>
Propentofylline .....	44
<b>Antidepressants.....</b>	<b>45</b>
Antidepressant-induced neurogenesis.....	45
Neurogenesis induced by electroconvulsive therapy .....	45
Neuroprotective effect of selective serotonin reuptake inhibitors .....	45
<b>Antiepileptic drugs as neuroprotectives.....</b>	<b>46</b>
Phenytoin .....	47
Valproic acid.....	47
Levetiracetam .....	47
<b>Antiinflammatory agents .....</b>	<b>48</b>
Aspirin.....	48
Interleukin-1 antagonists.....	48
COX-2 inhibitors .....	48
<i>Nimesulide</i> .....	49
<i>NS-398</i> .....	49
Minocycline .....	49
VP015 .....	50
<b>Anti-apoptosis agents.....</b>	<b>51</b>

Activated protein C .....	51
Calpain inhibitors .....	52
Caspase inhibitors .....	52
Clusterin .....	52
DNA binding drugs .....	53
Lithium .....	53
Omega-3 fatty acids .....	53
<i>Docosahexaenoic acid</i> .....	53
Poly (ADP-ribose) polymerase (PARP) inhibitors .....	54
Prevention of apoptosis by binding of proNGF to Sortilin .....	55
TRO19622 .....	55
<b>Antioxidants/free radical scavengers .....</b>	<b>55</b>
Free radical generation .....	55
Natural defenses against oxidative stress .....	56
Effects of oxidative damage .....	56
<i>Oxidative damage and aging</i> .....	56
<i>Neuronal damage by free radicals</i> .....	57
<i>Oxidative damage and neurodegenerative disorders</i> .....	57
Measures to control oxidative stress .....	57
<i>Categories of therapeutic antioxidants</i> .....	58
<i>Alpha-phenyl-tert-butyl nitron</i> .....	58
<i>Coenzyme Q10</i> .....	58
<i>Dihydroergocryptine</i> .....	59
<i>Flavonoids</i> .....	60
<i>Mitochondria-targeted antioxidants</i> .....	60
<i>Nanoparticles as neuroprotective antioxidants</i> .....	60
<i>Neuroleptics as antioxidants</i> .....	61
<i>Nitrones</i> .....	61
Translation of antioxidant neuroprotection from preclinical to clinical .....	61
<b>Carbon monoxide and heme oxygenase .....</b>	<b>62</b>
<b>Cell transplants .....</b>	<b>62</b>
Cells secreting neuroprotective substances .....	62
Stem cells .....	63
Stem cell activation for neuroprotection/regeneration by using glucocorticoids .....	63
<b>Cytokines .....</b>	<b>63</b>
Erythropoietin .....	63
<i>Non-erythropoietic EPO variants and mimics</i> .....	65
Granulocyte colony-stimulating factor .....	66
<b>Delta-opioid receptor agonists .....</b>	<b>66</b>
<b>FK960 .....</b>	<b>66</b>
<b>GABA agonists .....</b>	<b>67</b>
<b>Gene therapy .....</b>	<b>67</b>
<b>Glucagon-like peptide .....</b>	<b>68</b>
<b>Glatiramer acetate .....</b>	<b>68</b>
<b>Glutamate antagonists .....</b>	<b>69</b>
Neuroprotection by scavenging blood glutamate .....	70
N-acylethanolamines for protection against glutamatergic excitotoxicity .....	70
Glutamate transporters .....	70
Glutamate transporter-mediated neuroprotective effect of drugs .....	71
Neuroprotection by targeting KAI subunit of kainate receptor .....	71
<b>Glycine-proline-glutamate analogs .....</b>	<b>71</b>
<b>Herbal preparations .....</b>	<b>72</b>
Flavonoid wogonin .....	72
Ginseng .....	73
<b>Hydrogen sulfide .....</b>	<b>73</b>
<b>NMDA receptor ion channel complex .....</b>	<b>73</b>
NMDA receptor antagonists .....	74
<i>NPS 1506</i> .....	74
<i>NMDA NR2B subunit receptor antagonists</i> .....	75
<i>Ifenprodil</i> .....	75
<i>Memantine</i> .....	75
<i>Magnesium</i> .....	75
<i>NAALADase inhibitors</i> .....	76
<i>3,3-bis (3-fluorophenyl) propylamine</i> .....	76
<i>Gacyclidine (GK-11)</i> .....	76
<i>N-alkylglycines</i> .....	76
Partial NMDA agonists at glycine site .....	77
AMPA receptor modulators .....	77
Metabotropic glutamate receptor modulators .....	77
Cannabinoids .....	78
Dexanabinol .....	79

<b>Glutathione</b> .....	<b>79</b>
<b>Heat shock proteins</b> .....	<b>79</b>
<b>Hormones</b> .....	<b>80</b>
Estrogen and neuroprotection.....	80
<i>Neuroprotective effect of estrogen receptor ligands</i> .....	80
<i>Selective estrogen receptor modulators</i> .....	81
<i>Receptor-independent neuroprotective effects of estrogens</i> .....	81
<i>Mitochondrial mechanisms of estrogen neuroprotection</i> .....	82
Insulin.....	82
<b>Ion Channel modulators</b> .....	<b>82</b>
Calcium channel blockers.....	83
<i>Ziconotide</i> .....	83
Na <sup>+</sup> channel blockers.....	83
Neuroprotective potassium channel inhibitors.....	84
<b>Kynurenine inhibitors</b> .....	<b>84</b>
<b>Leukocyte adhesion inhibitors</b> .....	<b>85</b>
<b>Modafinil</b> .....	<b>85</b>
<b>Neural regeneration protein</b> .....	<b>86</b>
<b>Neurite outgrowth-promoting prostaglandin compounds</b> .....	<b>86</b>
<b>Neuroimmunophilins</b> .....	<b>86</b>
Cyclosporin-A.....	87
FK506.....	87
GPI 1485.....	87
Rapamycin.....	88
<b>Neurotrophic factors</b> .....	<b>88</b>
Activity-dependent neurotrophic factor.....	88
Bone morphogenetic proteins.....	89
Brain-derived neurotrophic factor.....	89
Ciliary neurotrophic factor.....	90
Fibroblast growth factors.....	90
Glial cell line-derived neurotrophic factor.....	91
Insulin-like growth factor.....	91
Nerve growth factor.....	91
Neurotrophins.....	92
Osteogenic protein-1.....	93
Pigment epithelium-derived factor.....	93
Transforming growth factor-β1.....	93
Vascular endothelial growth factor.....	93
Neurotrophic factor-related neuroprotective agents.....	94
<i>Amitriptyline as a TrkA and TrkB receptor agonist</i> .....	94
<i>Colivelin</i> .....	94
<i>Gambogic amide</i> .....	94
<i>Inosine</i> .....	95
<i>Meteorin</i> .....	95
<i>Oxygen-regulated protein 150 kD (ORP150)</i> .....	95
<i>Prosaptide</i> .....	95
<i>Siagoside (GM1 ganglioside)</i> .....	96
<i>Small molecule activators of the Trk receptors</i> .....	96
<b>Nicotine and nicotinic receptor agonists</b> .....	<b>97</b>
<b>Nitric oxide-based neuroprotection</b> .....	<b>98</b>
Nitric oxide synthase inhibitors.....	98
Nitric oxide mimetics.....	99
<b>Nootropics</b> .....	<b>99</b>
<i>Piracetam</i> .....	100
<b>Nutraceuticals and food constituents</b> .....	<b>100</b>
Creatine.....	100
Curcumin/curry.....	101
Glyceryltriacetate.....	102
Green tea.....	102
Nicotinamide.....	102
Resveratrol.....	103
<b>Osmotic diuretics</b> .....	<b>103</b>
Mannitol.....	103
Osteopontin.....	104
<b>Oxygen therapeutics</b> .....	<b>104</b>
Oxygen carriers.....	105
Hemoglobin-based oxygen carriers.....	105
Perfluorocarbons as oxygen carriers.....	106
Hyperbaric oxygen therapy.....	107
<b>Peptides</b> .....	<b>107</b>
C3-derived peptide for neuroprotection and neuroregeneration.....	107

Corticotropin-releasing hormone .....	107
Neuroprotective peptide NAP .....	108
Thyrotropin-releasing hormone .....	108
Vasoactive intestinal peptide (VIP) .....	109
<b>PPARs as drug targets for neuroprotection .....</b>	<b>109</b>
<b>Riluzole .....</b>	<b>109</b>
<b>Role of RNA interference in neuroprotection .....</b>	<b>110</b>
<b>Sigma receptor agonists as neuroprotective agents .....</b>	<b>110</b>
<b>Signaling pathway activator .....</b>	<b>112</b>
Fructose-1,6-bisphosphate .....	112
<b>Sir 2 group of proteins .....</b>	<b>112</b>
<b>Statins .....</b>	<b>113</b>
<b>Steroids .....</b>	<b>113</b>
Dehydroepiandrosterone .....	114
HF0220 .....	114
<b>Sulforaphane .....</b>	<b>114</b>
<b>Tauroursodeoxycholic acid .....</b>	<b>115</b>
<b>Tetanus toxin as a neuroprotective agent .....</b>	<b>115</b>
<b>Thrombolytic agents as neuroprotective agents .....</b>	<b>115</b>
<b>Uncoupling protein 2 .....</b>	<b>116</b>
<b>Vaccines as neuroprotectives .....</b>	<b>116</b>
<b>Vitamins as neuroprotective agents .....</b>	<b>116</b>
Vitamin B12 .....	116
<b>Non-pharmacological approaches to neuroprotection .....</b>	<b>117</b>
Environmental enrichment .....	117
Hypothermia .....	117
<i>Limitations of hypothermia .....</i>	<i>118</i>
<i>Hypothermic neuroprotection in hypoxia-ischemia .....</i>	<i>118</i>
Hibernation induced by hydrogen sulfide .....	119
Ketogenic diet .....	119
Preconditioning-induced neuroprotection .....	119
<i>Hypoxic preconditioning .....</i>	<i>120</i>
<i>Moderate stimulation of reactive oxygen species .....</i>	<i>120</i>
<i>Chemical preconditioning .....</i>	<i>121</i>
Transcranial magnetic stimulation .....	121
Electrical fields for improvement of cerebral function in neurodegeneration .....	122
Neuroprotective effect of exercise .....	122
Hibernation and neuroprotection .....	123
Suspended animation and neuroprotection .....	123
<b>3. Neuroprotection in Cerebrovascular Disease .....</b>	<b>125</b>
<b>Introduction .....</b>	<b>125</b>
<b>Epidemiology of stroke .....</b>	<b>125</b>
<b>Pathophysiology of cerebral ischemia .....</b>	<b>126</b>
Calcium overload .....	126
Ion channel dysfunction in stroke .....	127
Role of oxygen free radicals in cerebral ischemia .....	127
Role of nitric oxide in cerebral ischemia .....	127
Glutamate as a marker of stroke .....	127
Cerebral edema in stroke .....	128
Gene expression in response to cerebral ischemia .....	128
Induction of heat shock proteins in stroke .....	128
Role of cytokines and adhesion molecules in stroke .....	129
<i>Tumor necrosis factor (TNF)-<math>\alpha</math> .....</i>	<i>129</i>
<i>Interleukin (IL)-1 and IL-6 .....</i>	<i>129</i>
<i>Adhesion molecules .....</i>	<i>129</i>
DNA damage and repair in cerebral ischemia .....	130
Role of neurotrophic factors .....	130
<i>Problems requiring investigation of the role of NTFs in stroke .....</i>	<i>131</i>
Role of Poly(ADP-ribose) polymerase (PARP) gene .....	131
Role of protease-activated receptor 1 .....	131
<b>Reperfusion injury after cerebral ischemia .....</b>	<b>131</b>
<b>Neuroprotection according to zones in cerebral infarction .....</b>	<b>132</b>
Zone of ischemic infarction .....	132
Penumbra .....	132
<b>Current management of stroke .....</b>	<b>133</b>
Neuroprotection in stenosis of intracranial arteries .....	134
Neuroprotection in transient ischemic attacks .....	134
<b>Neuroprotective therapies for stroke .....</b>	<b>134</b>
Acid-sensing ion channel blockers .....	135
AMPA receptor antagonists as neuroprotectives for stroke .....	135

<i>Zonampanel</i> .....	135
Anti-apoptotic neuroprotectives .....	136
<i>NIM811</i> .....	136
<i>Creatine as neuroprotective in stroke</i> .....	136
<i>Lithium as a neuroprotective in stroke</i> .....	136
<i>TUDCA as a neuroprotective in stroke</i> .....	137
Antiepileptic drugs as neuroprotectives in stroke.....	137
<i>Tiagabine</i> .....	137
<i>Topiramate</i> .....	137
<i>Zonisamide</i> .....	138
Anti-HMGB1 monoclonal antibody .....	138
Antioxidant approaches .....	138
<i>Carnosine as a neuroprotective in stroke</i> .....	139
<i>Dehydroascorbic acid</i> .....	139
<i>Tocotrienols</i> .....	140
<i>Uric acid</i> .....	140
Antiglutamate compounds.....	140
<i>202W92</i> .....	140
<i>AR-R15896AR</i> .....	141
<i>MRZ 2/576</i> .....	141
<i>L-Phenylalanine</i> .....	141
Arimoclomol for stroke .....	141
Cardiac glycosides as neuroprotectives in stroke .....	142
Clenbuterol .....	142
Cox-2 inhibitors for ischemic stroke.....	142
Enoxaparin.....	143
Estrogen for stroke .....	143
Flavones for neuroprotection in stroke .....	144
Granulocyte-macrophage colony-stimulating factor for cerebral ischemia.....	145
Histamine H <sub>2</sub> -receptor antagonists .....	145
Inosine for stroke .....	145
<i>Intravenous immunoglobulin as neuroprotective in stroke</i> .....	146
Insulin-like growth factor-I.....	146
Ischemic preconditioning for neuroprotection in stroke .....	146
Ketone bodies .....	147
Minalocorticoid receptor blockade for neuroprotection.....	148
Multifunctional neuroprotective agents.....	148
<i>Nasal delivery of neuroprotective agents in stroke</i> .....	148
Neuroserpin as a neuroprotective in stroke .....	149
N-2-mercaptopropionyl glycine .....	149
NeuroAid .....	149
Neurotrophic factors as neuroprotectives for stroke.....	150
<i>AX200</i> .....	150
<i>Brain-derived neurotrophic factor</i> .....	150
<i>Neuregulin-1</i> .....	150
NO-based strategies for neuroprotection in cerebral ischemia .....	150
Peroxisome proliferator-activated receptor- $\gamma$ agonists .....	151
PGE <sub>2</sub> EP2 receptor activation .....	151
Pioglitazone for reduction of stroke risk in diabetes .....	151
Progesterone.....	151
Proteasome inhibitors.....	152
Statins for prevention and neuroprotection in stroke .....	152
SB-239063.....	153
Sildenafil .....	153
Src receptor blockade.....	154
Stroke vaccine.....	154
SUN N4057 .....	154
Thrombosis inhibitors .....	154
<i>Aspirin</i> .....	155
<i>Clopidogrel</i> .....	155
<i>Dipyridamole</i> .....	155
<i>CBL1309</i> .....	155
Neuroprotectives in reperfusion injury .....	156
Prevention of hemorrhage following ischemic stroke.....	156
Non-pharmacological neuroprotective therapies for stroke .....	157
<i>Preconditioning for neuroprotection against cerebral ischemia</i> .....	157
<i>Hypothermia for neuroprotection in acute stroke</i> .....	157
<i>Hyperbaric oxygen therapy for neuroprotection in acute stroke</i> .....	158
<i>Infrared laser therapy for ischemic stroke</i> .....	159
<i>Neurostimulation of sphenopalatine ganglion</i> .....	159
<i>Role of neurosurgical procedures for neuroprotection in stroke</i> .....	159

<i>Neurorehabilitation in relation to neuroprotection in stroke</i> .....	160
Cell therapy for stroke .....	160
Gene therapy for neuroprotection in cerebrovascular disease .....	161
<i>Neuroprotective genetic vaccine</i> .....	162
<i>COX-1/PGIS and COX-1 gene transfer in cerebral ischemia</i> .....	163
<i>Transfer of the bcl-2 gene for neuroprotection in cerebral ischemia</i> .....	163
<i>Neuroglobin gene therapy</i> .....	163
<i>Regulation of microRNAs</i> .....	163
Neuroprotective therapies for cerebral ischemia: clinical trials .....	164
<i>Albumin</i> .....	165
<i>Free radical scavengers</i> .....	165
<i>DP-b99</i> .....	167
<i>Erythropoietin as a neuroprotective in stroke</i> .....	167
Minocycline for neuroprotection in stroke .....	167
<i>Perindopril</i> .....	168
Failed clinical trials of neuroprotection in stroke .....	168
<i>Ancrod</i> .....	170
<i>Aptiganel</i> .....	170
<i>Cerovive (NXY-059)</i> .....	170
<i>Citicoline</i> .....	171
<i>Desmoteplase</i> .....	172
<i>SPD 502</i> .....	173
<i>Tirilazad mesylate</i> .....	173
<i>Selfotel (CGS 19755)</i> .....	173
<i>Lubeluzole</i> .....	174
<i>Nalmefene (Cervene)</i> .....	174
<i>Gavestinel (GV150526)</i> .....	175
<i>Nimodipine</i> .....	175
<i>Repinotan</i> .....	175
<i>Sipatrigine</i> .....	175
<i>Causes of failure of stroke trials</i> .....	176
<i>Measures for prevention of failures in stroke trials</i> .....	177
<b>Design of acute stroke trial to facilitate drug approval</b> .....	<b>179</b>
<b>The ideal neuroprotective agent for stroke</b> .....	<b>179</b>
<b>Future prospects for neuroprotection in stroke</b> .....	<b>180</b>

#### **4. Neuroprotection in CNS Trauma ..... 183**

<b>Introduction</b> .....	<b>183</b>
<b>Cerebral hypoxia/ischemia as a complication of trauma</b> .....	<b>183</b>
<b>Traumatic brain injury (TBI)</b> .....	<b>183</b>
Pathophysiology of TBI .....	183
<i>Immediate damage following TBI</i> .....	184
<i>Cerebral edema following TBI</i> .....	184
<i>Delayed damage following TBI</i> .....	185
<i>Mechanism of axonal damage after TBI</i> .....	185
<i>Role of neuroinflammation in TBI</i> .....	185
<i>Molecular events following TBI</i> .....	185
<i>BBB damage after TBI</i> .....	186
<i>Chronic traumatic encephalopathy</i> .....	186
<i>Changes in neurotrophic factors following TBI</i> .....	187
<i>Changes in neurotransmitters following TBI</i> .....	187
<i>A<math>\beta</math> deposition following TBI</i> .....	187
<i>Genetic influences on outcome following TBI</i> .....	188
Management of TBI.....	188
<i>Control of intracranial pressure and cerebral edema</i> .....	189
<i>Corticosteroids</i> .....	189
Neuroprotection in TBI.....	189
<i>Antiepileptic drugs for prevention of seizures and neuroprotection</i> .....	190
<i>Antioxidants</i> .....	191
<i>Barbiturates</i> .....	191
<i>- and <math>\gamma</math>-secretase inhibitors</i> .....	191
<i>Beta blockers</i> .....	192
<i>Bradykinin B<sub>2</sub> antagonists</i> .....	192
<i>Branched chain amino acids to ameliorate cognitive impairment in TBI</i> .....	192
<i>Cell cycle inhibitors for TBI</i> .....	193
<i>Creatine for neuroprotection in TBI</i> .....	193
<i>COX-2 inhibitors for neuroprotection in TBI</i> .....	193
<i>Cyclosporin for neuroprotection in TBI</i> .....	194
<i>Dexanabol for TBI</i> .....	194
<i>Erythropoietin for neuroprotection in TBI</i> .....	195
<i>Gold implants for neuroprotection in focal TBI</i> .....	195

KN 38-7271 .....	195
Magnesium sulfate .....	195
Neurotrophic factors for TBI .....	196
Neurosteroids as neuroprotective agents for TBI .....	197
Nicotinamide for neuroprotection in TBI .....	197
NMDA receptor antagonists .....	198
Non-NMDA receptor antagonists .....	198
Nogo-A inhibitor .....	198
NP-1 .....	198
Omega 3 fatty acids as neuroprotectives in TBI .....	199
Oxygen carriers for TBI .....	199
Polyethylene glycol for neuroprotection in TBI .....	200
Propofol for neuroprotection in TBI .....	200
Rapamycin as neuroprotective in TBI .....	200
Simvastatin as neuroprotective in TBI .....	201
Thyrotropin-releasing hormone analogs .....	201
Traxoprodil .....	201
Biological approaches to neuroprotection in TBI .....	202
Antisense approaches to TBI .....	202
Cell therapy for TBI .....	202
Gene therapy for TBI .....	203
Vaccine for TBI .....	203
Non-pharmaceutical approaches to neuroprotection in TBI .....	203
Hyperbaric oxygen therapy for TBI .....	203
Hypothermia .....	203
Reduction of microglial migration after TBI .....	204
Deep brain stimulation for TBI .....	204
Prophylactic neuroprotection against TBI .....	204
Role of physical exercise in protection against TBI .....	205
Clinical trials of neuroprotective agents in TBI .....	205
Failed clinical trials in TBI .....	206
Differences between clinical trials and studies in animal models of TBI .....	207
Subgroup analysis .....	207
Improving the clinical trial design .....	207
Clinical trials combining multipotential treatment strategies .....	208
Shortening the trial time .....	208
Concluding remarks and future prospects of neuroprotection in TBI .....	208
<b>Acute spinal cord injury (SCI) .....</b>	<b>209</b>
Epidemiology of SCI .....	209
Pathophysiology of SCI .....	209
Secondary mechanisms of SCI .....	210
Neurotrophic factor changes in SCI .....	211
Management of SCI .....	212
Pharmacological neuroprotective agents for SCI .....	213
4-aminopyridine(4-AP, famprodine) .....	213
Antibodies as neurite growth inhibitors in SCI .....	213
Bacterial enzyme chondroitinase ABC .....	214
CRL-5861 .....	214
Docosahexaenoic acid as neuroprotective in SCI .....	214
Erythropoietin as a neuroprotective in SCI .....	215
Free radical scavengers for neuroprotection in SCI .....	215
Gacyclidine .....	215
GYKI 52466 .....	216
Immunosuppressants as neuroprotectants in SCI .....	216
Matrix metalloproteinase inhibitors for SCI .....	216
Methylprednisolone .....	216
Minocycline as neuroprotective in SCI .....	217
Neurotrophic factors for neuroprotection after SCI .....	217
Nicotinamide adenine dinucleotide .....	218
Rho pathway and Rho antagonists in SCI .....	218
Selenium as a neuroprotective for SCI .....	219
Sialidase for enhancing recovery after SCI .....	219
Targeting the inflammatory response for neuroprotection in SCI .....	219
Uric acid as neuroprotective in SCI .....	220
Non-pharmacological approaches to SCI .....	220
Hyperbaric oxygen therapy .....	220
Hypothermia for SCI .....	220
Cell and gene therapy for SCI .....	220
Cell transplants .....	220
Gene therapy for SCI .....	222
Combined approaches to spinal cord injury .....	222

Discovery of new targets for neuroprotective therapies in SCI .....	223
Clinical trials in SCI .....	224

## **5. Neuroprotection in Neurodegenerative Disorders..... 227**

<b>Introduction .....</b>	<b>227</b>
<b>Pathomechanism of neurodegeneration .....</b>	<b>227</b>
Dual role of $\alpha$ -synuclein in neuroprotection and neurodegeneration .....	227
Lack of neurotrophic factors .....	228
Neuroinflammation in neurodegenerative disorders .....	228
Neurodegeneration associated with protein misfolding .....	228
<i>Modulation of neurodegeneration by molecular chaperones .....</i>	<i>228</i>
<i>Intrabodies targeting protein misfolding in neurodegeneration.....</i>	<i>229</i>
<i>Targeting in proteins aggregation to prevent amyloid formation.....</i>	<i>229</i>
<i>Tau and neurodegeneration.....</i>	<i>229</i>
Role of apoptosis in neurodegenerative disorders.....	230
Role of glia in neurodegeneration .....	230
Role of metals in neurodegeneration .....	230
Viral infections and neurodegeneration .....	231
<i>AIDS and the nervous system .....</i>	<i>231</i>
<i>Avian influenza as cause of neurodegeneration.....</i>	<i>232</i>
<b>Approaches to neuroprotection in neurodegenerative disorders.....</b>	<b>232</b>
Glutamate-based therapies for neurodegenerative disorders .....	233
<b>Parkinson's disease .....</b>	<b>233</b>
Epidemiology of Parkinson's disease .....	233
Pathophysiology of Parkinson's disease .....	234
<i>Oxidative stress.....</i>	<i>234</i>
<i>Excitotoxicity.....</i>	<i>235</i>
<i>Asynchronous neuronal activity.....</i>	<i>235</i>
<i>Apoptosis.....</i>	<i>236</i>
<i>Role of neurotrophic factors .....</i>	<i>236</i>
<i>Role of misfolding proteins .....</i>	<i>236</i>
<i>Genetic factors in PD.....</i>	<i>236</i>
<i>Alteration of dopamine homeostasis .....</i>	<i>238</i>
Neuroprotective strategies for PD based on pathomechanism .....	238
<i>RNAi screening to identify neuroprotective genes in a PD model .....</i>	<i>239</i>
Management of Parkinson's disease .....	239
Limitation of conventionally administered dopamine therapy .....	240
Treatment of dementia associated with Parkinson's disease.....	241
Neuroprotective therapy in Parkinson's disease.....	241
Neuroprotective effect of currently used drugs for Parkinson's disease.....	242
<i>Pramipexole .....</i>	<i>242</i>
<i>Rasagiline mesylate.....</i>	<i>242</i>
<i>Ropinirole .....</i>	<i>243</i>
<i>Selegiline.....</i>	<i>243</i>
Free radical scavengers for neuroprotection in Parkinson's disease.....	244
<i>Antioxidants.....</i>	<i>244</i>
<i>Melatonin.....</i>	<i>244</i>
<i>Tea extracts as neuroprotectives.....</i>	<i>245</i>
<i>Nicotine as a neuroprotective in PD .....</i>	<i>245</i>
Non-pharmacological strategies for neuroprotection in Parkinson's disease.....	246
<i>Preventive effect of exercise and environmental enrichment.....</i>	<i>246</i>
<i>Low-calorie diet .....</i>	<i>246</i>
Research in neuroprotection for Parkinson's disease .....	246
<i>Activation of the hedgehog signaling pathway.....</i>	<i>247</i>
<i>Activation of endogenous stem cells and neural precursors .....</i>	<i>247</i>
<i>Adenosine A<sub>2</sub> receptor antagonists .....</i>	<i>248</i>
<i>Anti-apoptotic strategies for PD .....</i>	<i>248</i>
<i>Conserved dopamine neurotrophic factor for PD.....</i>	<i>249</i>
<i>Heat shock protein 70 (Hsp70) .....</i>	<i>249</i>
<i>Neuroprotective effect of DJ-1 protein .....</i>	<i>249</i>
<i>Nrf2-mediated neuroprotection in PD.....</i>	<i>249</i>
<i>Omega-3 polyunsaturated fatty acids .....</i>	<i>250</i>
<i>RAB3B overexpression.....</i>	<i>250</i>
<i>Sirtuin 2 inhibitors for neuroprotection in PD .....</i>	<i>250</i>
<i>Statins and PD.....</i>	<i>251</i>
<i>Targeting Bax.....</i>	<i>251</i>
<i>Tobacco smoke constituents.....</i>	<i>251</i>
<i>Synergistic effect of dopamine and cannabinoid agonists in PD .....</i>	<i>252</i>
<i>Vitamin D for neuroprotection in PD .....</i>	<i>252</i>
Clinical trials of neuroprotection in Parkinson's disease .....	252
<i>CEP-1347.....</i>	<i>254</i>

<i>Creatine and minocycline</i> .....	254
<i>Neurotrophic factors</i> .....	254
<i>PYM50028</i> .....	257
<i>Safinamide</i> .....	257
<i>Cell therapies</i> .....	258
<i>Gene therapy</i> .....	258
<i>RNAi therapy for Parkinson's disease</i> .....	261
<i>Vaccine for PD</i> .....	261
Evaluation of neuroprotective therapies for PD .....	261
Current status and future challenges for neuroprotection in PD .....	263
<b>Alzheimer's disease</b> .....	<b>263</b>
Introduction .....	263
Pathomechanism of Alzheimer's disease .....	264
<i>Role of glutamate transport dysfunction in AD</i> .....	265
<i>Role of neurotrophic factors in the pathomechanism of AD</i> .....	265
Management of Alzheimer's disease .....	265
Neuroprotection in Alzheimer's disease .....	266
Inhibition of amyloid $\beta$ -protein aggregation .....	267
<i>Secretase inhibitors</i> .....	267
<i>AN-1792</i> .....	267
<i>Monoclonal antibody m266</i> .....	268
<i>Inhibition of the transformation of spherons into amyloid plaques</i> .....	268
<i>Clioquinol</i> .....	268
<i>FKBP52 for neuroprotection from Cu toxicity in AD</i> .....	269
<i>Phenserine</i> .....	269
<i>Colostrinin</i> .....	270
Inhibition of neuroinflammation .....	270
<i>MW01-5-188WH</i> .....	270
<i>Etanercept</i> .....	271
Neurotrophic factors/ gene therapy .....	271
<i>NGF gene therapy</i> .....	271
<i>Neotrofin (leteprenim potassium, AIT-082)</i> .....	273
<i>AL-108</i> .....	273
Targeting plasminogen activator inhibitor type-1 gene .....	273
Estrogen .....	274
ABS-205 .....	274
Nimodipine .....	274
Antioxidants .....	275
<i>NSAIDS</i> .....	275
<i>P-3012</i> .....	275
<i>Vitamin E</i> .....	275
Memantine .....	275
Dimebon .....	277
Cerebrolysin .....	278
Ginko biloba .....	278
Tetrahydrocannabinol for neuroprotection in AD .....	279
CPI-1189 .....	279
Ladostigil tartrate .....	280
Phosphodiesterase inhibitors .....	280
PPAR- $\gamma$ gamma agonists .....	280
Role of statins in reducing the risk of Alzheimer's disease .....	281
Combined therapeutic approaches to Alzheimer's disease .....	281
Clinical trials in Alzheimer's disease .....	282
Future prospects of neuroprotection in AD .....	288
<b>Huntington's disease</b> .....	<b>289</b>
Epidemiology of HD .....	289
Pathophysiology of HD .....	289
Management of Huntington's disease .....	290
Neuroprotection in Huntington's disease .....	291
<i>Antipsychotic D<sub>2</sub> and 5-HT<sub>1A</sub> antagonists</i> .....	292
<i>Caspase inhibitors</i> .....	292
<i>Clioquinol for HD</i> .....	292
<i>Creatine for stabilizing bioenergetic defects</i> .....	292
<i>Cysteamine</i> .....	293
<i>Drugs that block inappropriate calcium release from neurons</i> .....	293
<i>Enhancing protease activity for clearance of mHtt</i> .....	293
<i>Eicosapentaenoic acid</i> .....	294
<i>Free radical scavengers</i> .....	294
<i>Histone deacetylase inhibitors</i> .....	294
<i>Inhibitors of polyglutamine aggregation HD</i> .....	294
<i>Pridopidine</i> .....	295

<i>Simvastatin as a neuroprotective in HD</i> .....	295
<i>Single chain Fv antibodies</i> .....	296
<i>SIRT2 inhibitors for neuroprotection in HD</i> .....	296
<i>Synaptic activation of NMDA receptors</i> .....	296
<i>Tetrabenazine</i> .....	296
<i>Combinatorial therapy and targeting multiple pathways in HD</i> .....	297
<i>Cell transplants</i> .....	297
<i>Neurotrophic factors and gene therapy</i> .....	298
<i>RNAi therapy for Huntington's disease</i> .....	298
<b>Amyotrophic lateral sclerosis (ALS)</b> .....	<b>299</b>
Epidemiology of ALS.....	299
Pathophysiology of ALS.....	299
Neuroprotective therapies for ALS.....	301
<i>Activated protein C</i> .....	302
<i>AEOL 10150</i> .....	303
<i>AIMSPRO</i> .....	303
<i>Arimoclomol for ALS</i> .....	303
<i>Antisense therapy</i> .....	304
<i>Ceatine for ALS</i> .....	304
<i>Ceftriaxone for ALS</i> .....	304
<i>Coenzyme Q10 for ALS</i> .....	305
<i>COX-2 inhibitors for ALS</i> .....	305
<i>Dexpropipexole</i> .....	305
<i>Diallyl trisulfide</i> .....	306
<i>Erythropoietin for ALS</i> .....	306
<i>Gene therapy for ALS</i> .....	306
<i>Glatiramer acetate</i> .....	307
<i>Insulin-like growth factor</i> .....	307
<i>Ketogenic diet for neuroprotection in ALS</i> .....	307
<i>Lenalidomide</i> .....	308
<i>Lithium for neuroprotection in ALS</i> .....	308
<i>Methylcobalamin</i> .....	309
<i>Minocycline for ALS</i> .....	309
<i>Miscellaneous neurotrophic factors for ALS</i> .....	309
<i>ONO-2506 for ALS</i> .....	310
<i>Riluzole</i> .....	310
<i>RNAi-based therapy for ALS</i> .....	310
<i>Sodium phenylbutyrate</i> .....	311
<i>Stem cell therapy</i> .....	311
<i>Talampanel</i> .....	311
<i>Tamoxifen</i> .....	311
<i>TRO19622 as neuroprotective for ALS</i> .....	312
<i>Vaccination for ALS caused by SOD1 mutations</i> .....	312
<i>Vascular endothelial growth factor for ALS</i> .....	312
<i>Clinical trials of neuroprotective therapies for ALS</i> .....	313
Concluding remarks and future prospects of neuroprotection in ALS .....	315
<b>Spinal and bulbar muscular atrophy</b> .....	<b>315</b>
<b>6. Neuroprotection in Miscellaneous Neurological Disorders</b> .....	<b>317</b>
<b>Dementias due to miscellaneous causes</b> .....	<b>317</b>
Age-related dementia .....	317
<i>Enhancing endogenous neurotrophic support of the aging brain</i> .....	317
<i>Pharmacological approaches for treatment of age-related dementia</i> .....	318
<i>Physical exercise to prevent decline of mental function with aging</i> .....	319
Vascular dementia .....	319
<i>A test for prediction of dementia in persons with vascular risk factors</i> .....	319
<i>Management of subcortical vascular dementia</i> .....	320
Dementia with Lewy bodies .....	321
Creutzfeldt-Jakob disease .....	321
<b>TDP-43 proteinopathy and neurodegenerative diseases</b> .....	<b>322</b>
<b>Genetic disorders with neurodegeneration</b> .....	<b>322</b>
Batten's disease.....	322
Friedrich's ataxia .....	323
Niemann-Pick type C disease.....	324
<b>Epilepsy</b> .....	<b>324</b>
Mechanisms of neuronal damage in epilepsy .....	324
Strategies for neuroprotection in epilepsy .....	325
<i>Control of seizures and neuroprotection</i> .....	326
<i>Responsive Neurostimulator System</i> .....	327
<i>Neuroprotective effect of estrogens in epilepsy</i> .....	327
<i>Cell therapy for neuroprotection in epilepsy</i> .....	327

<i>Gene therapy for neuroprotection in epilepsy</i> .....	328
<b>Multiple sclerosis</b> .....	<b>329</b>
Introduction .....	329
Epidemiology of multiple sclerosis .....	329
Pathophysiology .....	329
Current management of multiple sclerosis.....	330
Specific therapies for MS based on pathomechanism .....	331
Neuroprotection in multiple sclerosis .....	331
<i>Neuroprotection by control of progressive forms of multiple sclerosis</i> .....	333
<i>Neuroprotection by controlling autoimmune inflammation in the brain</i> .....	333
<i>Remyelination for neuroprotection in multiple sclerosis</i> .....	334
Agents for neuroprotection in multiple sclerosis .....	334
<i>Angiotensin-II inhibitors</i> .....	334
<i>Antiglutamate agents</i> .....	334
<i>Antioxidants for neuroprotection in MS</i> .....	334
<i>Antisense and RNAi approaches to MS</i> .....	335
<i>Cell therapy for multiple sclerosis</i> .....	335
<i>Cladribine</i> .....	336
<i>Dalfampridine in MS</i> .....	337
<i>DNA vaccine for MS</i> .....	337
<i>Erythropoietin as a neuroprotective in MS</i> .....	337
<i>Fingolimod (FTY720)</i> .....	338
<i>Fusokine composed of GM-CSF and IL-15 for immune suppression</i> .....	338
<i>Gene therapy for MS</i> .....	339
<i>IVIg for MS</i> .....	339
<i>Laquinimod</i> .....	339
<i>MBP8298</i> .....	340
<i>Monoclonal antibodies for MS</i> .....	340
<i>Natalizumab</i> .....	340
<i>Natural human antibodies for repair of myelin</i> .....	341
<i>Neurotrophic factors for multiple sclerosis</i> .....	341
<i>Recombinant T-cell ligands</i> .....	342
<i>Statins for MS</i> .....	342
<i>Concluding remarks on neuroprotection in MS</i> .....	343
<b>Chronic inflammatory demyelinating polyradiculoneuropathy</b> .....	<b>343</b>
Neuroprotection in CIDP .....	343
<b>Neuroprotection in transverse myelitis</b> .....	<b>344</b>
<b>Neuroprotection in decompression sickness</b> .....	<b>344</b>
<b>Neuroprotection in hydrocephalus</b> .....	<b>345</b>
Neuroprotection in normal pressure hydrocephalus .....	345
<b>Neuroprotection in infections of the CNS</b> .....	<b>346</b>
Neuroprotection in bacterial meningitis .....	346
<i>Mechanism of neural injury in bacterial meningitis</i> .....	346
<i>Strategies for neuroprotection</i> .....	346
Neuroprotection in AIDS dementia .....	347
Neuroprotective approach to rabies .....	348
Neuroprotection in cerebral malaria.....	348
<b>Neuroprotection in hypertensive encephalopathy</b> .....	<b>349</b>
<b>Neuroprotection in toxic encephalopathies</b> .....	<b>349</b>
Hepatic encephalopathy .....	349
Encephalopathy due to organophosphorus poisoning .....	350
Neuroprotection against chemotherapy-induced brain damage .....	350
Neuroprotection against alcohol.....	351
<i>Alcoholic neurologic disorders</i> .....	351
<i>Fetal alcohol syndrome</i> .....	351
<i>Pathogenesis of alcohol-induced damage to the nervous system</i> .....	351
<i>Neuroprotection against neurotoxicity of alcohol</i> .....	352
<b>Neuroprotection in sleep apnea</b> .....	<b>352</b>
<b>Neuroprotection in hypoglycemic coma</b> .....	<b>353</b>
<b>Neuroprotection in neonatal hypoxic-ischemic brain injury</b> .....	<b>354</b>
<b>Neuroprotection in mitochondrial dysfunction</b> .....	<b>356</b>
Mitochondrial permeability transition .....	356
Mitochondrial approaches for neuroprotection.....	356
Methylene blue .....	357
Role of nanolasers in evaluation of mitochondrial neuroprotectants .....	358
Neuroprotection in mitochondrial encephalopathies .....	358
<b>Neuroprotection in schizophrenia</b> .....	<b>358</b>
<b>Neuroprotection of the optic nerve and the retina</b> .....	<b>359</b>
Neuroprotection in optic nerve trauma.....	359
<i>Potential regeneration of the optic nerve</i> .....	359
<i>Subthreshold transpupillary thermotherapy for protection of RGCs</i> .....	360

Neuroprotection of optic nerve in glaucoma.....	360
<i>Aminoguanidine as a neuroprotective in glaucoma</i> .....	361
<i>Antiglutamate agents for neuroprotection of optic nerve</i> .....	361
<i>Betaxolol</i> .....	362
<i>NGF eye drops</i> .....	362
<i>Targeting A<math>\beta</math> in glaucoma treatment</i> .....	362
<i>TNF-<math>\alpha</math> blockers for neuroprotection in glaucoma</i> .....	362
<i>Concluding remarks about neuroprotection in glaucoma</i> .....	363
Neuroprotection in retinal ischemia .....	363
<i>Endogenous neuroprotection in the retina</i> .....	363
<i>-adrenoceptor antagonists</i> .....	364
<i>Brimonidine as a neuroprotective in ischemic retinopathy</i> .....	364
<i>Thioredoxin as a neuroprotective agent in retinal ischemia</i> .....	364
<i>Erythropoietin for neuroprotection of retinal ischemia</i> .....	365
<i>Gene therapy for retinal neuroprotection</i> .....	365
<i>Hyperbaric oxygen for central retinal artery occlusion</i> .....	365
Protection against oxygen-induced retinopathy .....	366
Neuroprotection in macular degeneration.....	366
<i>Antiangiogenic agents</i> .....	367
<i>Protection of retinal cells from oxidative-stress-induced apoptosis</i> .....	367
<i>Nutritional protection against AMD</i> .....	368
<i>Cell therapy for macular degeneration</i> .....	368
<i>Gene therapy for retinal degeneration</i> .....	369
<i>RNAi-based treatments for AMD</i> .....	369
Neuroprotection in proliferative diabetic retinopathy.....	369
Companies developing products for retinal neuroprotection .....	370
<b>Neuroprotection in hearing loss.....</b>	<b>371</b>
Causes of hearing loss.....	371
Pathomechanism of hearing loss .....	372
Prevention and treatment of hearing loss .....	372
<i>Hyperbaric oxygen for hearing loss</i> .....	373
<i>Stem cell therapy for hearing loss</i> .....	373
<i>Auditory hair cell replacement by gene therapy</i> .....	374
<i>Pharmaceutical approaches to hearing loss</i> .....	374
<b>Neuroprotection of peripheral nerves .....</b>	<b>375</b>
Neuroprotective agents for peripheral nerves .....	375
<i>Acetyl-L-carnitine for peripheral nerve injuries</i> .....	375
<i>Atorvastatin for peripheral nerve injuries</i> .....	375
<i>Erythropoietin for neuroprotection in peripheral nerve injuries</i> .....	376
Neuroprotection in peripheral nerve injuries .....	376
<i>Role of hyperbaric oxygen in peripheral nerve injuries</i> .....	376
<i>Role of neurotrophic factors in peripheral nerve injuries</i> .....	377
<i>Pharmacological approaches to Schwann cells</i> .....	377
<i>Role of gene therapy in neuroprotection of injured peripheral nerves</i> .....	377
<i>Schwann cell transplantation for peripheral nerve injury</i> .....	377
Peripheral neuropathy .....	378
<i>Neuroprotection in diabetic neuropathy</i> .....	378
<i>Cell therapy for neuroprotection in diabetic neuropathy</i> .....	378
<i>Neuroprotection in chemotherapy-induced neuropathy</i> .....	378
<b>7. Neuroprotection during Anesthesia and Surgery .....</b>	<b>381</b>
<b>Introduction .....</b>	<b>381</b>
<b>Anesthetic agents as neuroprotectives .....</b>	<b>381</b>
Barbiturates .....	381
<i>Thiopental</i> .....	382
Etomidate .....	382
Propofol.....	383
Ketamine .....	383
Gaseous anesthetics.....	383
<i>Isoflurane</i> .....	383
<i>Xenon</i> .....	384
Local anesthetics .....	384
<b>Monitoring of CNS function during anesthesia and surgery .....</b>	<b>385</b>
Monitoring of cerebral function .....	385
Monitoring of spinal cord function during surgery on the spine.....	385
<b>Neuroprotection during cardiovascular procedures .....</b>	<b>385</b>
CNS complications of cardiac surgery .....	385
Neuroprotective strategies during cardiac surgery.....	386
<i>Neuroprotection during coronary artery bypass grafting</i> .....	387
<i>Neuroprotection before anticipated or induced cardiac arrest</i> .....	388
Surgery on the aorta .....	388

<b>Spinal protection during cardiovascular surgery.....</b>	<b>389</b>
<b>Cerebral protection during organ transplantation surgery.....</b>	<b>389</b>
<b>Cerebral protection during neurosurgery.....</b>	<b>389</b>
Cerebral angiography and endovascular surgery.....	389
Cerebral protection during surgery for arteriovenous malformations.....	390
Cerebral protection during surgery of intracranial aneurysms.....	390
Management of subarachnoid hemorrhage.....	391
<i>Vasospasm associated with subarachnoid hemorrhage.....</i>	<i>391</i>
Cerebral protection during carotid endarterectomy.....	392
Neuroprotection during spinal surgery.....	393
Neuroprotective measures prior to surgery.....	393
<b>8. Commercial aspects of Neuroprotective Therapy.....</b>	<b>395</b>
<b>Introduction.....</b>	<b>395</b>
<b>The financial burden of CNS damage.....</b>	<b>395</b>
<b>Markets for neuroprotective therapies.....</b>	<b>395</b>
Markets according to therapeutic areas.....	395
Values of neuroprotective therapies in major world markets.....	397
Unmet needs in neuroprotectives.....	397
<b>Future prospects of neuroprotective therapies.....</b>	<b>398</b>
Challenges in neuroprotective drug development.....	399
Promising areas of research in neuroprotection.....	399
<i>Autoreactive antibodies.....</i>	<i>399</i>
<i>Protective genes.....</i>	<i>400</i>
<b>9. References.....</b>	<b>401</b>

## Tables

Table 1-1: Historical landmarks in the development of neuroprotection.....	23
Table 1-2: Intrinsic neuroprotective factors.....	24
Table 1-3: Common features of pathophysiology of brain damage in diseases.....	30
Table 1-4: Place of neuroprotection in management of CNS disorders.....	31
Table 1-5: Indications for the use of neuroprotection.....	31
Table 2-1: A classification of neuroprotective agents.....	39
Table 2-2: The neuroprotective effect of antiepileptic drugs.....	46
Table 2-3: Neuroprotective affect of minocycline in animal models.....	50
Table 2-4: Classification of antioxidants or free radical scavengers with neuroprotective potential.....	58
Table 2-5: Role of erythropoietin in the nervous system.....	64
Table 2-6: Ionotropic glutamate receptors.....	69
Table 2-7: Classification of metabotropic glutamate receptors (mGluRs).....	69
Table 2-8: Methods for preconditioning-induced neuroprotection.....	120
Table 3-1: Cerebrovascular diseases that are relevant to neuroprotection.....	125
Table 3-2: Neuroprotective strategies for stroke.....	134
Table 3-3: Neuroprotective gene therapy in animal stroke models.....	161
Table 3-4: Neuroprotective agents in clinical development for acute cerebrovascular disease.....	164
Table 3-5: Some failed trials for neuroprotective therapy for stroke.....	168
Table 3-6: Preclinical assessment of neuroprotective agents in acute stroke models.....	177
Table 4-1: Current conventional management of traumatic brain injury.....	188
Table 4-2: Neuroprotective strategies for traumatic brain injury.....	189
Table 4-3: Ongoing or completed clinical trials for neuroprotection in TBI.....	205
Table 4-4: Discontinued or failed clinical trials for neuroprotection in TBI.....	206
Table 4-5: Secondary mechanisms in spinal cord injury.....	211
Table 4-6: Neuroprotective and regenerative approaches for SCI.....	212
Table 4-7: Clinical trials for neuroprotection in SCI.....	224
Table 5-1: Glutamate-based therapies in clinical development for neurodegenerative disorders.....	233
Table 5-2: Prevalence of Parkinson's disease in major markets 2009-2019.....	234
Table 5-3: Factors in the etiology of Parkinson's disease.....	234
Table 5-4: Strategies for the treatment of Parkinson's disease.....	239
Table 5-5: Neuroprotective therapies in preclinical development for Parkinson's disease.....	246
Table 5-6: Current clinical trials of neuroprotective therapies for Parkinson's disease.....	252
Table 5-7: Failed clinical trials of neuroprotective therapies for Parkinson's disease.....	253
Table 5-8: Evaluation of neuroprotective agents for PD.....	262
Table 5-9: Cholinergic approaches to the treatment of Alzheimer's disease.....	265
Table 5-10: Neuroprotective agents for Alzheimer's disease.....	266
Table 5-11: Clinical trials in Alzheimer disease.....	282
Table 5-12: Discontinued, failed or inconclusive clinical trials of Alzheimer disease.....	286
Table 5-13: Strategies for discovery of neuroprotective therapies for AD.....	288
Table 5-14: Neuroprotective approaches in HD.....	291

Table 5-15: Classification of neuroprotective agents for amyotrophic lateral sclerosis .....	302
Table 5-16: Clinical trials of neuroprotective therapies for ALS .....	313
Table 5-17: Failed or discontinued trials of neuroprotective therapies for ALS.....	314
Table 6-1: Therapeutic approaches to subcortical vascular dementia .....	320
Table 6-2: Pharmacological neuroprotection against the sequelae of seizures .....	326
Table 6-3: Neuroprotective effect of AEDs in animal models of status epilepticus (SE).....	326
Table 6-4: Specific therapies for multiple sclerosis based on postulated pathomechanisms.....	331
Table 6-5: Neuroprotective therapies for multiple sclerosis .....	332
Table 6-6: Approaches to neuroprotection in neonatal hypoxia-ischemia.....	354
Table 6-7: Drugs with neuroprotective effect at mitochondrial level .....	357
Table 6-8: Neuroprotection of the optic nerve in glaucoma .....	361
Table 6-9: Strategies for neuroprotection in retinal ischemia .....	363
Table 6-10: Novel neuroprotective strategies against retinal degeneration .....	366
Table 6-11: Companies developing products for retinal neuroprotection .....	370
Table 6-12: Causes of sensorineural hearing impairment .....	371
Table 6-13: Strategies for prevention and treatment of sensorineural hearing loss.....	372
Table 6-14: Agents for neuroprotection of the peripheral nervous system .....	375
Table 7-1: CNS complications associated with cardiac procedures.....	385
Table 7-2: Neuroprotective strategies for cardiac surgery .....	387
Table 7-3: Medical and surgical methods of cerebral vasospasm management.....	391
Table 7-4: Neuroprotection by prevention of vasospasm.....	392
Table 8-1: Neuroprotective market values 2009-2019 .....	396
Table 8-2: Values of neuroprotective therapies in major world markets from 2009-2019 .....	397

## Figures

Figure 2-1: NMDA receptor ion channel complex.....	73
Figure 2-2: Neuroprotective effect of galantamine .....	97
Figure 2-3: Mechanism of neuroprotective effect of sigma-1 receptor agonists .....	111
Figure 3-1: Some steps in the ischemic cascade and site of action of neuroprotectives .....	126
Figure 3-2: A roadmap for neuroprotection .....	178
Figure 4-1: Cascade of events following traumatic brain injury .....	184
Figure 4-2: Pathomechanism of acute spinal cord injury .....	210
Figure 5-1: Neuroprotective strategies against death of dopamine-containing neurons in PD .....	238
Figure 6-1: Common mechanisms of neural damage in cerebral ischemia and seizures.....	325
Figure 6-2: Role of neuroprotection in epilepsy and its treatment .....	325
Figure 8-1: Unmet therapeutic needs in neuroprotective therapies.....	398